

PTO/SB/08A (10-21)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form P449A/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	10/077,719	
			Filing Date	02/15/2002	
			First Named Inventor	RODRIGUEZ	
			Art Unit	1614	
			Examiner Name	PAK	
Sheet	1	of	2	Attorney Docket Number	PS 00-07-01

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>2</sup>	Document Number	Publication Date: MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number • Kind Code <sup>3</sup> (if known)			
		US. 5,972,684	10-26-1999	Bandman, et al.	
		US.			
		US.			
		US.			
		US.			
		US.			
		US.			
		US.			
		US.			
		US.			
		US.			
		US.			
		US.			
		US.			
		US.			
		US.			
		US.			
		US.			
		US.			

FOREIGN PATENT DOCUMENTS							
Examiner Initials <sup>1</sup>	Cite No. <sup>2</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>4</sup>	Number <sup>1</sup> • Kind Code <sup>5</sup> (if known)				

Examiner Signature		Date Considered	6/2/03
-----------------------	--	--------------------	--------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 904.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 15 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

**Complete If Known**

Application Number	10/077,719
Filing Date	02/15/2002
First Named Inventor	RODRIGUEZ
Group Art Unit	1614
Examiner Name	PAK
Attorney Docket Number	PS 00 07 01

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A	REICHLMEIER K, ERMINI M, SCHLECHT H.P., "[Age-dependent enzymatic changes in human cerebral cortex (author's transl)]" [Article in German], <i>Aktuelle Gerontol</i> 1978 Aug;8(8):441-8. - ABSTRACT ONLY	
	B	MEIER_RUGE, W., IWANGOFF, P., REICHLMEIER, K., AND SANDOZ, P., "Neurochemical findings in the Aging Brain" <i>Adv. Biochem Psychopharmacology</i> 1980;23:323-38. - ABSTRACT ONLY	
	C	CABISCO, E. AND LEVINE, R. L., "Carbonic anhydrase III. Oxidative modification <i>in vivo</i> and loss of phosphatase activity during aging", <i>J. Biol. Chem.</i> 1995 Jun 16;270(24):14742-7. - ABSTRACT ONLY	
	D	HUANG W, SMITH SE, CHESLER M., "Addition of carbonic anhydrase augments extracellular pH buffering in rat cerebral cortex.", <i>J Neurophysiol</i> 1995 Oct;74(4):1806-9. - ABSTRACT ONLY	
	E	BOREN K, FRESKGARD PO, CARLSSON U., "A comparative CD study of carbonic anhydrase isoenzymes with different number of tryptophans: impact on calculation of secondary structure content.", <i>Protein Sci.</i> 1996 Dec;5(12):2479-84. - ABSTRACT ONLY	
	F	PUSCAS I, COLTAU M, PASCA R. "Nonsteroidal anti-inflammatory drugs activate carbonic anhydrase by a direct mechanism of action." <i>J Pharmacol Exp Ther</i> 1996 Jun;277(3):1464-6. - ABSTRACT ONLY	
	G	HENKIN, R.I., MARTIN, B.M., AND AGARWAL, R. P., "Efficacy of exogenous oral zinc in treatment of patients with carbonic anhydrase VI deficiency", <i>Am J Med Sci</i> 1999 Dec;318(6):392-405. - ABSTRACT ONLY	
	H	CHAI F, TRUONG_TRAN AQ, EVDOKIOU A, YOUNG GP, ZALEWSKI PD., "Intracellular zinc depletion induces caspase activation and p21 Waf1/Cip1 cleavage in human epithelial cell lines.", <i>J Infect Dis.</i> 2000 Sep;182 Suppl 1:S85-92. - ABSTRACT ONLY	

Examiner  
Signature

Date

Considered

6/2/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.